B+
Bull case
25%
Probability
Target price
$37.00
Analysis reference price unavailable
Analysis 2026-08-20 · RankAlpha Sentiment Codex
SMTI
Sanara MedTechCNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
55%
Probability
Target price
$35.00
Analysis reference price unavailable
Analysis 2026-08-20 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$27.00
Analysis reference price unavailable
Analysis 2026-08-20 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-20
Recent news sentiment (30D)
+72.0
Positive
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+60.0
Score
AI commentary
News tone remains positive because of the announced merger and ongoing surgical growth, but the Q2 report was mixed: adjusted EPS beat while revenue missed consensus and GAAP operating profitability weakened. The current price is close to headline merger value, so the setup is primarily event-driven with limited incremental upside. Post-print analyst revisions and market-reaction attribution are unavailable; social, options, short-interest, and employee-review data are also unavailable, reducing confidence.
RankAlpha Sentiment Codex - 2026-08-20
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-20catalystMixed Q2 print may cap near-term upsideMedium impact
Zacks reported adjusted EPS of $0.05 versus $0.02 consensus, but revenue of $28.14 million missed consensus by 4.3%. The company reported 9% revenue growth, 93% gross margin, $1.8 million operating income versus $2.5 million a year earlier, and $5.0 million Adjusted EBITDA. [#SEC-8K-2026-08-11] [#PR-EARNINGS-2026-08-11]
2026-11-18eventMiMedx merger consideration anchors valuation near $35Medium impact
The announced transaction provides $33.00 cash plus 0.4735 MiMedx shares, valued at approximately $2.00 per SMTI share at announcement. Closing remains subject to customary conditions, including stockholder and regulatory approval. [#8-K-2026-07-29]
2027-08-20catalystOsStic launch and surgical portfolio penetrationMedium impact
Management stated that OsStic remains on track for introduction in the first quarter of 2027. Q2 soft-tissue repair sales increased 11% year over year, supporting a longer-term operating case if execution continues. [#SEC-8K-2026-08-11]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-20 • Updated nightlySource: Internal modelMethodology